CC
EW icon

Centiva Capital’s Edwards Lifesciences EW Stock Holding History

Centiva Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,900
Closed -$374K – 1899
2023
Q4 		$374K Buy
+4,900
New +$341K 0.01% 1103
2022
Q4 		– Sell
-5,000
Closed -$413K – 1439
2022
Q3 		$413K Buy
+5,000
New +$481K 0.01% 939
2020
Q1 		– Sell
-90,000
Closed -$7M – 706
2019
Q4 		$7M Hold
90,000
– – 0.34% 59
2019
Q3 		$6.6M Hold
90,000
– – 0.4% 43
2019
Q2 		$5.54M Buy
+90,000
New +$5.44M 0.33% 65

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Centiva Capital's EW Position: Q3 2025 in Review

Centiva Capital sold out of Edwards Lifesciences (EW) in Q3 2025, closing a stake of 18,515 shares — an estimated $1.45M sold.

Centiva Capital first reported a position in EW in Q2 2019 and held it in 14 quarters. The position peaked at $1.87M in Q1 2024. 1,254 funds tracked by Wall St. Rank hold EW as of Q3 2025.

  • Centiva Capital reported no remaining Edwards Lifesciences position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 18,515 Edwards Lifesciences shares in Q3 2025, an estimated $1.45M.
  • Centiva Capital first reported a position in Edwards Lifesciences in Q2 2019 and held it in 14 quarters.
  • Centiva Capital's Edwards Lifesciences position peaked at $1.87M in Q1 2024.
  • 1,254 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.